July 31, 2026 · Phase 3 readout
KPTI Phase 3 readout: a negative outcome, -72.6%
On July 31, 2026, Selinexor (combination therapy) — Karyopharm Therapeutics Inc. (Relapsed/Refractory Diffuse Large B-cell Lymphoma) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -72.6% in the window around the event. It had already run -25.8% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$7.01
1d before
$1.92
Event day
$1.92
1d after
$1.91
5d after
Our prediction vs. the result
CatalystAlert called this one up (+2.6% expected); the stock actually moved -72.6%. Model confidence at the time: 40%.
See the full scored track recordPre-catalyst setup
-25.8%
30-day run-up
9384%
30-day volatility
5.4×
volume spike